Protara’s cell therapy touts BCG-naïve treatment potential in Phase II
Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin…
News
AI can reduce R&D costs to alleviate looming patent cliff pressures
FDA appoints Tracy Beth Høeg as fifth CDER head this year
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints
Remote monitoring could reduce patient burden and improve outcomes
Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours
FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS
Imvax to explore FDA pathway for glioblastoma candidate despite PFS miss
